Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona, USA
Adult Bone Marrow Transplant Service, New York City, Manhattan, USA.
BMJ Support Palliat Care. 2019 Dec;9(4):425-433. doi: 10.1136/bmjspcare-2018-001742. Epub 2019 Apr 4.
Multiple studies have questioned the benefit of neutropenic diets in decreasing infections in patients with cancer, but recent surveys showed that such diets are still prescribed. In this study, we sought to evaluate the effectiveness of neutropenic diet in decreasing infection and mortality in neutropenic patients with cancer with neutropenia. This review is an update of a previously published systematic review.
We searched different databases to identify comparative studies that investigated the effect of neutropenic diet compared with regular diet in neutropenic adults and children with cancer. We conducted random-effects meta-analyses using the Der-Simonian and Laird method to pool treatment effects from included studies. Outcomes of interest were mortality, bacteremia/fungemia, major infections, quality of life, and the composite outcome for neutropenic fever and/or infection.
We included six studies (five randomised) with 1116 patients, with 772 (69.1%) having underwent haematopoietic cell transplant. There was no statistically significant difference between neutropenic diet and regular diet in the rates of major infections (relative risk [RR] 1.16; 95% CI 0.94 to 1.42) or bacteremia/fungemia (RR 0.96; 95% CI 0.60 to 1.53). In haematopoietic cell transplant patients, neutropenic diet was associated with a slightly higher risk of infections (RR 1.25; 95% CI 1.02 to 1.54). No difference in mortality was seen between neutropenic diet and regular diet (RR 1.08, 95% CI 0.78 to 1.50).
There is currently no evidence to support the use of neutropenic diet or other food restrictions in neutropenic patients with cancer. Patients and clinicians should continue to follow the safe food-handling guidelines as recommended by the U.S. Food and Drug Administration.
多项研究质疑在减少癌症患者中性粒细胞减少症相关感染方面,给予中性粒细胞减少症饮食的益处,但最近的调查显示此类饮食仍在开具。本研究旨在评估中性粒细胞减少症饮食在减少中性粒细胞减少症癌症患者中性粒细胞减少症相关感染和死亡率方面的有效性。这是一项先前发表的系统评价的更新。
我们检索了不同的数据库,以确定比较研究,这些研究调查了中性粒细胞减少症饮食与癌症中性粒细胞减少症成人和儿童的常规饮食相比的效果。我们使用 Der-Simonian 和 Laird 方法进行随机效应荟萃分析,以汇总纳入研究的治疗效果。感兴趣的结局包括死亡率、菌血症/真菌感染、主要感染、生活质量以及中性粒细胞减少性发热和/或感染的复合结局。
我们纳入了六项研究(五项随机研究),共 1116 例患者,其中 772 例(69.1%)接受了造血细胞移植。中性粒细胞减少症饮食与常规饮食在主要感染发生率(相对风险 [RR] 1.16;95%CI 0.94 至 1.42)或菌血症/真菌感染(RR 0.96;95%CI 0.60 至 1.53)方面无统计学差异。在造血细胞移植患者中,中性粒细胞减少症饮食与感染风险略有增加相关(RR 1.25;95%CI 1.02 至 1.54)。中性粒细胞减少症饮食与常规饮食之间的死亡率无差异(RR 1.08,95%CI 0.78 至 1.50)。
目前没有证据支持在癌症中性粒细胞减少症患者中使用中性粒细胞减少症饮食或其他食物限制。患者和临床医生应继续遵循美国食品和药物管理局推荐的安全食品处理指南。